Cargando…

Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis

BACKGROUND: Short-course, rifamycin-based regimens could facilitate scale-up of tuberculosis preventive therapy (TPT), but it is unclear how stringently tuberculosis (TB) disease should be ruled out before TPT use. METHODS: We developed a state-transition model of a TPT intervention among two TPT-el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kendall, Emily A., Hussain, Hamidah, Kunkel, Amber, Kubiak, Rachel W., Trajman, Anete, Menzies, Richard, Drain, Paul K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670249/ https://www.ncbi.nlm.nih.gov/pubmed/34903214 http://dx.doi.org/10.1186/s12916-021-02189-w

Ejemplares similares

Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda
por: Sekaggya Wiltshire, Christine, et al.
Publicado: (2014)

Fatal poisoning by isoniazid and rifampicin
por: Sridhar, A., et al.
Publicado: (2012)

Isoniazid- and rifampicin-induced thrombocytopenia
por: Yakar, Fatih, et al.
Publicado: (2013)

Cost-Effectiveness of Quantiferon®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil
por: Steffen, Ricardo Ewbank, et al.
Publicado: (2013)

Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
por: Anderson, Ronald, et al.
Publicado: (2018)

Protective Effects of Metallothionein on Isoniazid and Rifampicin-Induced Hepatotoxicity in Mice
por: Lian, Yong, et al.
Publicado: (2013)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co–therapy
por: Li, Feng, et al.
Publicado: (2013)

Effectiveness of ellagic acid on isoniazid-rifampicin induced liver damage in rats
por: Ambrose, Samuel Stephen, et al.
Publicado: (2013)

Hepatoprotective Activity of Heptoplus on Isoniazid and Rifampicin Induced Liver Damage in Rats
por: Sankar, M., et al.
Publicado: (2015)

Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury
por: Wang, Chao, et al.
Publicado: (2016)

Simultaneous Spectrophotometric Determination of Rifampicin, Isoniazid and Pyrazinamide in a Single Step
por: Asadpour-Zeynali, Karim, et al.
Publicado: (2016)

Toxicoproteomic Profiling of hPXR Transgenic Mice Treated with Rifampicin and Isoniazid
por: Brewer, Christopher Trent, et al.
Publicado: (2020)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI
por: Oxlade, Olivia, et al.
Publicado: (2013)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Development and In Vitro Release of Isoniazid and Rifampicin-Loaded Bovine Serum Albumin Nanoparticles
por: Ge, Zhaohui, et al.
Publicado: (2018)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Isoniazid and Rifampicin Produce Hepatic Fibrosis through an Oxidative Stress-Dependent Mechanism
por: Biswas, Ayan, et al.
Publicado: (2020)

Improved Stability of Rifampicin in the Presence of Gastric-Resistant Isoniazid Microspheres in Acidic Media
por: Mwila, Chiluba, et al.
Publicado: (2020)

Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis
por: Sun, Bingqi, et al.
Publicado: (2021)

Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS
por: Souza, Josiane Maria Oliveira, et al.
Publicado: (2014)

Hepatoprotective activity of Ficus religiosa leaves against isoniazid+rifampicin and paracetamol induced hepatotoxicity
por: Parameswari, Sundaramoorthi Angala, et al.
Publicado: (2013)

Evaluation of Biochip System in Determining Isoniazid and Rifampicin Resistances of Mycobacterium Tuberculosis in Sputum Samples
por: Lu, Wei, et al.
Publicado: (2012)

Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis
por: Cilfone, NA, et al.
Publicado: (2015)

Rapid Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using Real-Time PCR
por: Sahebi, Leyla, et al.
Publicado: (2016)

Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India
por: Munir, Asma, et al.
Publicado: (2019)

Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid
por: Tang, Peijun, et al.
Publicado: (2017)

Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates
por: Muthaiah, Muthuraj, et al.
Publicado: (2017)

Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes
por: Su, Qiang, et al.
Publicado: (2021)

Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018
por: Sayfutdinov, Zayniddin, et al.
Publicado: (2021)

Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda
por: Micheni, Lisa Nkatha, et al.
Publicado: (2021)

Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats
por: Naji, Khalid Mohammed, et al.
Publicado: (2021)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study
por: Ramachandran, Geetha, et al.
Publicado: (2023)

Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa
por: Traoré, Afsatou Ndama, et al.
Publicado: (2023)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2riia8j0h71sb2au0htohcis6